Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:43:08.207Z.
Calculation as of: 2026-10-06T15:43:08.207Z.
Quote observation: 2026-10-06T15:40:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6b7402e8e4aad00529a5dc64304a2ec9485b3d7feb734bca750ca78a67bf3000
PE RATIO
N/A
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Pacific Biosciences of California, Inc.
Market Cap
$826.20M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$799.93M
PE Ratio
N/A
TTM Avg
694.69
3Y Avg
438.87
5Y Avg
438.87
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pacific Biosciences of California, Inc. (PACB) | $826.20M | N/A | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $817.67M | N/A | 197.34 | 197.34 | 197.34 |
| Jade Biosciences, Inc. (JBIO)vs › | $835.90M | N/A | N/A | N/A | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $840.45M | N/A | 151.06 | 53.96 | 49.56 |
| Beta Bionics, Inc. (BBNX)vs › | $843.41M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $805.59M | 11.39 | 9.51 | 9.54 | 15.29 |
| Apnimed, Inc. (APMD)vs › | $804.43M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $850.32M | N/A | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $799.93M | N/A | 694.69 | 438.87 | 438.87 |
| AdaptHealth Corp. (AHCO)vs › | $796.60M | N/A | 16.88 | 41.08 | 41.08 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.66
Forward EPS (Est.)
$-0.46
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2021-05-06 | 270.67 |
| 2021-05-05 | 277.11 |
| 2021-05-04 | 282.89 |
| 2021-05-03 | 303.00 |
| 2021-04-30 | 331.67 |
| 2021-04-29 | 372.00 |
| 2021-04-28 | 373.67 |
| 2021-04-27 | 373.78 |
| 2021-04-26 | 362.56 |
| 2021-04-23 | 344.00 |
| 2021-04-22 | 338.67 |
| 2021-04-21 | 335.89 |
| 2021-04-20 | 323.33 |
| 2021-04-19 | 329.00 |
| 2021-04-16 | 350.33 |
| 2021-04-15 | 365.00 |
| 2021-04-14 | 361.67 |
| 2021-04-13 | 370.28 |
| 2021-04-12 | 341.56 |
| 2021-04-09 | 357.33 |
| 2021-04-08 | 372.11 |
| 2021-04-07 | 361.67 |
| 2021-04-06 | 394.44 |
| 2021-04-05 | 383.67 |
| 2021-04-01 | 375.78 |
| 2021-03-31 | 370.11 |
| 2021-03-30 | 332.78 |
| 2021-03-29 | 318.11 |
| 2021-03-26 | 341.44 |
| 2021-03-25 | 339.33 |
| 2021-03-24 | 329.22 |
| 2021-03-23 | 362.89 |
| 2021-03-22 | 386.56 |
| 2021-03-19 | 371.44 |
| 2021-03-18 | 354.11 |
| 2021-03-17 | 387.00 |
| 2021-03-16 | 371.56 |
| 2021-03-15 | 391.89 |
| 2021-03-12 | 376.56 |
| 2021-03-11 | 394.44 |
| 2021-03-10 | 356.44 |
| 2021-03-09 | 348.67 |
| 2021-03-08 | 304.11 |
| 2021-03-05 | 325.22 |
| 2021-03-04 | 319.78 |
| 2021-03-03 | 344.06 |
| 2021-03-02 | 381.56 |
| 2021-03-01 | 391.33 |
